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OUTTERSON

All pain, no GAIN: need for prudent
antimicrobial use provisions to complement
the GAIN Act
Kevin Outterson, J.D.
Associate Professor of Law & Director of the Health Law Program, Boston University; Editor in Chief, Journal
of Law, Medicine & Ethics
The development of new antibiotics without having mechanisms to insure their appropriate use is much
like supplying your alcoholic patients with a finer brandy. (Dennis Maki, IDSA meeting, 1998 [1, 2])
Only one health care bill is likely to pass Congress in this election year: the Prescription Drug User
Fee Act V (PDUFA V). Every five years, the FDA and
the drug and device industries renegotiate the user fees
and regulatory priorities for the FDA. PDUFA V is the
fifth generation in this process. This bill is very likely to
pass Congress this summer because many jobs at the
FDA are no longer funded from general federal appropriations, but come from these user fees. If the bill doesn’t
pass, many people at the FDA will be furloughed or fired.
Since it is a “must pass” bill with bipartisan support, PDUFA V has attracted additional provisions, hoping to hitch a ride and thus become law. The Generating
Antibiotic Incentives Now (GAIN) Act is one prominent
example. The GAIN Act is prominently featured in both
the House and Senate versions of PDUFA V.
The stated objectives of the GAIN Act include
increased surveillance of resistant bacteria, more responsible use of existing antibiotics, and increased incentives
to develop new antibiotics. However, the current draft of

the GAIN Act does not provide any binding requirements
to implement antimicrobial stewardship, appropriate use,
and conservation. It focuses exclusively on bringing new
antibiotics to market quickly, without any changes whatsoever to patterns of use in either human or animal populations. More brandy for the alcoholics.
It didn’t start out this way. The Infectious Diseases Society of America (IDSA) testified before Congress on March 8, 2012, and asked for both “strong incentives to spur new anti-infective research and development (R&D) and promote antimicrobial stewardship.” [3] While the IDSA’s primary focus has long been
on promoting new antimicrobial drugs, this testimony
notably included many proposals (advocated by public
health organizations such as APUA) for preserving and
extending the useful life of existing treatments as well.
They suggested creating a new regulatory pathway for
“special purpose limited medical use drugs” which would
be strictly limited to appropriate antimicrobial use. IDSA
called for payors to take a more active role in appropriate
use and value-based reimbursement for diagnostics. IDSA called for implementation of effective antimicrobial
stewardship programs as a condition of participation in
Medicare and Medicaid. IDSA also specifically recom-
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mended a robust surveillance system to “promote meascalled for the Centers for Disease Control and Prevention
urement of antibiotic usage across all health care settings
(CDC) to spend $10 million per year in surveillance, to
and support adoption and implementation of comprehentrack the resistance profiles of the new drugs approved
sive antimicrobial stewardship programs across all health
under GAIN. Neither proposal made the cut. The only
care settings to promote the appropriate use of antibiotamendment that might be considered friendly to appropriics.” Finally, they suggested that drug companies develate use is proposed section 906 of the Senate bill, which
op a plan for educating health care providers on the apcalls for a study by the National Academies on alternative
propriate use of new antibiotics and “to reinforce precaubusiness models for antimicrobial R&D, including prize
tions to reduce the risk of resistance.”
funds. [4-5]
As of late April 2012, none of these provisions
At this point, public health would be better
are included in the latest House or Senate versions. What
served if GAIN did not pass as part of PDUFA V. Any
has survived is an entirely one-sided emphasis on bringnew incentives for rushing antibiotics to market must be
ing new antibiotics to market quickmatched by similar commitments to
ly, even if the safety data is less
stewardship and appropriate use. [6The
current
draft
of
the
complete and without regard to ap7] Value-based reimbursement of
GAIN
Act
does
not
provide
propriate use. The GAIN Act will
both antibiotics and companion diagany
binding
requirements
to
add 5 or more years of data exclunostics should include strong support
implement
antimicrobial
sivity on to the end of patent terms
for appropriate use. [8-9] Otherwise,
stewardship,
appropriate
use,
for “qualified infectious disease
we might succeed at meeting the
and
conservation.
products,” extending the effective
IDSA’s goal of 10 new drugs by
patent period by about 40%, from 12
2020, but fail in the ultimate goal of
to 17 years. In economic terms, these extensions in efhaving effective antimicrobials at the moment of need
fective patent life will eventually cost the US health care
due to accelerating resistance. [10]
system several billion dollars in prescription drug expensThe correct policy isn’t simply conservation or
es due to the delayed introduction of generic antibiotics.
new production; we need both, in a balanced approach.
But, in a perfect Washington game, these expenses will
As currently drafted, GAIN is not balanced, but this
not count against the GAIN Act when the Congressional
could be corrected this summer in the Conference ComBudget Office scores the bill. As the IDSA testimony
mittee before Congress passes PDUFA V.
points out: “IDSA’s exclusivity proposals will likely not
Professor Outterson is an appointed member of
score a cost to the federal government for the next decade
the Antimicrobial Resistance Working Group of the OID/
or two, given the average amount of patent life typically
Board of Scientific Counselors, CDC and a faculty assoremaining on new antibiotics at the time they are apciate at the Harvard Center for Communicable Disease
Dynamics.
proved. Major companies, including GlaxoSmithKline
(GSK) and Pfizer, agree with IDSA’s assessment.”
In addition to the IDSA testimony, in early April
References
2012, several stewardship proposals were made to con1. Fishman N. Antimicrobial stewardship. Am J Med 2006;
gressional staff during bipartisan discussions on the
119:S53-S61; discussion S62-S70.
2. Harbarth S. Should the development of new antibiotics be
GAIN Act. One proposal was to limit the new GAIN
a public health priority? Cur Op Crit Care 2007; 13:554incentives to companies that met appropriate use or stew556.
ardship targets set by the FDA. In other words, the feder3. IDSA, Promoting anti-infective development and antimicrobial stewardship through the U.S. Food and Drug Adal government would agree to spend billions to bring new
ministration Prescription Drug User Fee Act (PDUFA)
antibiotics to market, but only if the companies were
Reauthorization, House Committee on Energy and Comcareful with how they were used. Another proposal
merce, Subcommittee on Health, March 8, 2012.
14

APUA Clinical Newsletter Vol.30 No.1 • © 2012 APUA

Electronic copy available at: http://ssrn.com/abstract=2071244

OUTTERSON
4.
5.

6.
7.

So AD, et al. Towards new business models for R&D for
novel antibiotics. Drug Resist Updates 2011; 14:88-94.
Outterson K, Hollis A, Pogge T. Combatting antibiotic
resistance through the Health Impact Fund in THE GLOBALIZATION OF HEALTH CARE (Glenn I. Cohen, ed.,
Oxford University Press, forthcoming 2012) (available at
ssrn).
Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet
Infect Dis 2007; 7:559-566.
Outterson K. The legal ecology of resistance: the role of

© 2012 APUA • APUA Clinical Newsletter Vol.30 No.1

antibiotic resistance in pharmaceutical innovation.
Cardozo Law Rev 2010; 31:613-678.
8. Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting
public health goals. Health Aff 2010; 29:1689-1696.
9. Kesselheim AS, Outterson K. Improving antibiotic markets for long term sustainability. Yale J Health Policy,
Law & Ethics 2011; 11:101.
10. Outterson K, Powers JH, Gould IM, Kesselheim AS.
Questions about the 10 x ’20 initiative. Clin Infect Dis
2010; 51:751-752.

15

